PURPOSE: To prepare the titled compound useful as a blood platelet coagulation inhibitor, vasodilator, antiulcer agent, etc., easily, in high yield, by reacting 5,6- dehydroprostaglandin F2α compound with a mercury compound, and treating the reaction product with a boron hydride compound.
CONSTITUTION: The 5,6-dehydroprostaglandin F2α compound of formula I [the solid line and the dotted line between 13 and 14 sites are double or triple bond; G is CO2R5 or CONR6R7 (R5 is 1W10C alkyl, etc.; R6 and R7 are 1W10C alkyl, etc.); R1 is H, methyl, etc.; R2 is unsubstituted 5W8C alkyl, etc.; R3 and R4 are 2W7C acyl, etc.] is made to react with a mercury (II) compound (e.g. mercuric acetate, mercuric trifluoroacetate, etc.) in an inert organic solvent in the pressence of tri(1W6C)alkylamine. The reaction product is treated with a boron hydride compound (e.g. sodium borohydride) to obtain the objective compound of formula II (G1 is the same as G or COOH; R31 and R41 are the same as R3 and R4 or H).
SUZUKI MASAAKI
YANAGISAWA AKIRA
KUROZUMI SEIJI
| JPS5484653A | 1979-07-05 | |||
| JPS5455560A | 1979-05-02 |
Next Patent: NOVEL SULFONIC ACID ESTER OF HYDROXYCOUMARIN, MANUFACTURE AND MEDICINE